FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Radius Health, Inc. and Menarini Group Announce Positive Phase 3 Topline Results from the EMERALD Study ”
Radius Health, Inc. (NASDAQ: RDUS) surged over 37% in premarket trading after the company and the Menarini Group announced positive topline results from the EMERALD study.
The study was designed to evaluate elacestrant as a monotherapy versus the current standard of care and EMERALD met both primary endpoints, showing statistically significant PFS in the overall population and ESR1 mutation subgroup.
For more information, please visit: Radius Health, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post “The Buzz” Show: Radius Health, Inc. (NASDAQ: RDUS) & Menarini Group Announce EMERALD Study Results first appeared on Financial Buzz .
For further details see:
“The Buzz” Show: Radius Health, Inc. (NASDAQ: RDUS) & Menarini Group Announce EMERALD Study Results